Vincerx Pharma Inc. (VINC)
0.27
0.01 (3.01%)
At close: Apr 11, 2025, 9:41 AM
3.01% (1D)
| Bid | 0.27 |
| Market Cap | 1.41M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -30.07M |
| EPS (ttm) | -15.85 |
| PE Ratio (ttm) | -0.02 |
| Forward PE | -2.59 |
| Analyst | Buy |
| Ask | 0.28 |
| Volume | 235,688 |
| Avg. Volume (20D) | 1,098,888 |
| Open | 0.26 |
| Previous Close | 0.26 |
| Day's Range | 0.26 - 0.28 |
| 52-Week Range | 0.22 - 20.20 |
| Beta | 1.39 |
About VINC
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat sol...
Industry Biotechnology
Sector Healthcare
IPO Date May 27, 2020
Employees 12
Stock Exchange NASDAQ
Ticker Symbol VINC
Website https://vincerx.com
Analyst Forecast
According to 1 analyst ratings, the average rating for VINC stock is "Buy." The 12-month stock price forecast is $40, which is an increase of 14714.81% from the latest price.
Stock Forecasts1 day ago
-49.24%
Vincerx Pharma shares are trading lower after the ...
Unlock content with
Pro Subscription
2 months ago
-5.45%
Vincerx Pharma shares are trading higher after the company and Oqory announced Phase 1a/1b results for Anti-TROP2 ADC OQY-3258 in solid tumors. Additionally, there is a proposed merger between the two companies to advance Phase 2 trials and build an ADC pipeline.
